IMMUNE PHARMACEUTICALS, INC. (NASDAQ:IMNP) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07
As set forth in our February 21, 2018 current report on Form 8-K, on February 15, 2018, Immune Pharmaceuticals Inc. (the “Company”) held its annual meeting of stockholders on Proposals 1, 2, 3, 5 and 6 of its Definitive Proxy Statement, filed with the U.S. Securities and Exchange Commission on January 26, 2018 (“Proxy Statement”). On February 23, 2018, the Company resumed its annual meeting of stockholders, at which time the Company’s stockholders approved Proposal 4 of our Proxy Statement involving the ratification, to Delaware General Corporation Law sec. 204, of our previously approved reverse stock split (which had been effected in April 2017).
On December 1, 2017, there were 17,904,173 shares of common stock issued and outstanding, of which at least 11,156,087 were represented at the February 23, 2018 meeting, which was sufficient to constitute a quorum.
Set forth below are the final voting results for Proposal No. 4:
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
| 9,004,151 | 1,934,791 | 217,145 | – |
| Item 7.01 | Regulation FD Disclosure. |
On February 26, 2018, the Company issued a press release announcing the results of the Company’s February 23rd annual meeting. The information contained in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.
The information contained in this Item 7.01 and in the press release attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
| Exhibit Number | Description |
| 99.1 | Press Release, dated February 27, 2018 |
IMMUNE PHARMACEUTICALS INC ExhibitEX-99.1 2 tv487305_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immune Pharmaceuticals Announces Outcome of Annual Meeting of Stockholders Englewood Cliffs,…To view the full exhibit click here
About IMMUNE PHARMACEUTICALS, INC. (NASDAQ:IMNP)
Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.
